Day 1: Sunday, December 3, 2023

SESSION 1: Epidemiology and prospects for global elimination of viral hepatitis

Plenary Lecture: The US HCV elimination plan – what will actually be required

Norah Terrault - University of Southern California, USA

The rocky road to HBV cure

Marc Ghany - NIH, USA

Viral discovery programs: Are there still new hepatitis viruses to be found?

Adrian Di Bisceglie - Saint Louis University, USA

back to top - digital content

Day 2: Monday, December 4, 2023

William H. Prusoff HEP DART Lifetime Achievement Award lecture

Progress in hepatitis B: A 4-decade Journey through three continents

Anna Lok - University of Michigan Medical Center, USA

Session 2: Overview of viral hepatitis, pediatrics challenges and NASH

Plenary lecture: Challenges in accessing pediatric formulations for children with HBV and HCV

Manal El-Sayed - Ain Shams University, Egypt

Incorporating Real-World Evidence into the Regulatory Pathway

Michael Fried - University of North Carolina at Chapel Hill

Prospects for Gene and Cell Therapy of MASLD / MASH

Scott Friedman - Icahn School of Medicine at Mount Sinai, USA

Oral Abstract Session 1

Hedgehog signaling and metabolic responses drive CD8 T cell hyperfunction in advanced liver diseases

Jiafeng Li - University of Ottawa, Canada

Comparative analysis of human, rodent and snake kolmioviridae replication

Zoé Denis - Centre National de la Recherche Scientifique (CNRS), France

cccDNA clearance and elimination in HBV infected chimeric mice with humanized liver

Yong-Yuan Zhang, HBVtech, USA

A rhesus macaque model of HIV/HBV co-infection

Sreya Biswas - Oregon Health and Science University, USA

Impact of human immunodeficiency virus infection on liver and cardiovascular outcomes in patients with metabolic dysfunction associated steatotic liver disease

Robert Wong - Stanford University, USA

Safety and efficacy of REP 2139-Mg against chronic HBV / HDV co-infection with advanced liver disease

Andrew Vaillant - Replicor, Inc., Canada

Hepatitis B basic science, immunology, and therapeutics (Hepatitis B Foundation sponsored session)

Plenary Lecture: Immunological and drug approaches to HBV in animal models

Hélène Strick-Marchand - Pasteur Institute, France

Do all patients need immunomodulatory therapy to achieve HBV cure?

Adam Gehring - Toronto General Hospital Research Institute, Canada

Depletion of cccDNA/pgRNA by long-term NUC therapy- HBV Cure

Ashwin Balagopal - Johns Hopkins University School of Medicine, USA

Developing liver-targeted DHQ compounds with activity against hepatitis B virus

Yanming Du - Blumberg Institute, USA

Session 4: New advances in NASH, MASLD, fibrosis, cirrhosis, HCC treatment

Plenary Lecture: Metabolite-induced activation of auto-aggressive T cells as cause of liver damage

Percy Knolle - Technical University of Munich, Germany

Unmet Needs for management of patients with cirrhosis

Raj Reddy - University of Pennsylvania, USA

Advances through collaboration in SLD

Veronica Miller, University of California, Berkley, USA

DEBATE SESSION: HBsAg clearance is attainable with HBV cure therapies currently in clinical trials 

Moderators

back to top - digital content

Day 3: Tuesday, December 5, 2023

Session 5: From bench to bedside: Preclinical and clinical updates on hep B elimination

Plenary lecture: Assessing the progress towards HBV curative regimens & gene editing approaches

Fabien Zoulim - University of Lyon, France

HBV elimination: are therapeutic vaccines or T-cell therapy an option?

Ulrike Protzer - Technical University of Munich, Germany

HBV silencing: epigenetic modulation of the hepatitis B virus reservoir

Maura Dandri, University Medical Center Hamburg-Eppendorf, Germany

ORAL ABSTRACT SESSION II

Transgenic rhesus macaques expressing human sodium taurocholate co-transporting polypeptide are susceptible to hepatitis B infection

Ben Burwitz - Oregon Health and Science University, USA

Preclinical efficacy, safety and immunogenicity of CLB-3000: a potential treatment for patients with chronic Hepatitis B

Aileen Rubio - ClearB Therapeutics, USA

Antigen-Targeting to CD180 for the treatment of chronic HBV infection

Alan Wahl - Abacus Biosciences, USA

Session 6 (Industry Session): Advances in therapeutics for NASH, NAFLD, and liver disease

Epi Genetic Editing for the Treatment of HBV

Brian Cosgrove - Tune Therapeutics, USA

Progress on Madrigal’s NASH product and other assets

Becky Taub - Madrigal Pharmaceuticals, USA 

Genetics of HSD17B13, GSK4532990, and NASH/MASH

Audrey Chu - GSK, United Kingdom

Precision Bioscience’s PBGENE-HBV Program: A potentially curative strategy to eliminate cccDNA and inactivate integrated HBV DNA through gene editing

Emily Harrison - Precision Biosciences, USA

Jeff Smith - Precision Biosciences, USA

Review of poster session

SESSION 7 (Industry session): Getting closer to HBV curative approaches

A summary of Janssen learnings with JNJ-3989 siRNA for HBsAg lowering: virological and immunological changes in plasma and liver.

Heather Davis - VP R&D Hepatitis (J&J), Belgium

Oliver Lenze - Senior Director Clinical Microbiology & Immunology (J&J), Belgium

Long-term dosing of chronic hepatitis B infected subjects with the capsid assembly modulator ALG-000184

Larry Blatt - Aligos Therapeutics, USA

Addressing the unmet need for a functional cure in chronic hepatitis B infection

Carey Hwang - Vir Bio, USA

Progress towards and functional cure for hepatitis B

Karen Sims - Arbutus BioPharma, USA

No resistance detected through 8 years of TAF treatment in CHB patients and reduce HBV integration in patients with HBsAg loss

Jenny Svarovskaia - Gilead, USA

back to top - digital content

Day 4: Wednesday, October 4, 2023

Session 8: Biomarkers, subviral particles, and mitochondrial dysfunction in the context of viral hepatitis and chronic liver disease

Plenary lecture: Host cell factors associated with HBV virions and subviral particles and their role in the viral replication cycle

Ralf Bartenschlager - University of Heidelberg, Germany

Serum biomarkers to follow-up chronic hepatitis B

Harry Janssen - Erasmus Medical Center, the Netherlands

Hepatitis viruses, mitochondria, and CD38

Poonam Mathur - University of Maryland, USA

New HBV biomarkers: how will they change our treatment endpoints

Jordan Feld - University of Toronto, Canada

Session 9: Immunotherapy and immune responses towards a functional cure

Plenary Lecture: How to distinguish HBsAg derived from integrated HBV DNA and from episomal HBV DNA

Geoff Dusheiko - Kings College Hospital, United Kingdom

Immune responses mediating HBV functional cure

Georg Lauer - Harvard Medical School, USA

Oral Abstract Session III

Impact of IFNα on hepatocyte proteome in chronically-infected primary human hepatocytes

Lefteris Michailidis - Emory University, USA

Design of a small-molecule bispecific tether (miniBiT) for the treatment of influenza infections and expansion of the platform to treat chronic hepatitis B

Imrul Shahriar - Purdue University, USA

First-in-human application of a novel HBsAg-specific TCR T cell therapy (SCG101) shows antiviral and anti-tumor effects in patients with HBV-related hepatocellular carcinoma 

Ulrike Proztzer - Technical University of Munich, Germany

Session 10: Treatment and elimination of HCV in underserved populations

Treating people with hepatitis C where they are

Jennifer Price - University of California, San Francisco, USA

Co-location of HCV and OUD Care in People Who Inject Drugs: A Critical Component of HCV Elimination

Elana Rosenthal - University of Maryland, USA

Oral Abstract Session IV

Hepatitis C virus RNA is 5’ capped with flavin adenine dinucleotide

Lizandro Rene Rivera-Rangel - University of Copenhagen - Co-HEP, Denmark

Promises and pitfalls of implementing the FIND-C artificial intelligence/machine learning algorithm to improve screening efficiency in a real-world clinical environment

Bruce Kreter - Gilead Sciences, USA

Business discussion session (Non-CME accredited) 

Business of therapeutics for liver disease

Tavi Yehudai

Great Point Partners, LLC, USA

back to top - digital content

Day 5: Thursday, December 7, 2023

SESSION 11: Non-BC viral hepatitis: epidemiology, pathogenesis, and treatment

Plenary Lecture: Update on entry inhibitors to treat HBV and HDV infection

Stephan Urban - Heidelberg University, Germany

Bulevirtide for HDV

Tarik Asselah - Hopital Beaujon, APHP, France

Surprising antiviral activity of dihydroxyquinolones against hepatitis A virus

You Li - University of North Carolina at Chapel Hill, USA

Oral Abstract Session V

Low prevalence of HDV testing and worse disease outcomes among HDV patients in NYC – results from the INSIGHT database

Lauren Alpert - Icahn School of Medicine at Mount Sinai, USA

REP 2139 targets the hepatitis delta virus (HDV) ribonucleoprotein (RNP) and exerts a direct antiviral effect on HDV replication

Massimo Levrero - INSERM, France

Early virological efficacy of the monoclonal antibody VIR-3434 and siRNA VIR-2218 for the treatment of chronic hepatitis D virus: preliminary results from the Phase 2 SOLSTICE trial

Tarik Asselah - Hôpital Beaujon, France

Transient alanine transaminase increase during bepirovirsen treatment coincides with hepatitis B surface antigen decline in participants with chronic hepatitis B virus infection not currently on nucleos(t)ide analog therapy

Jennifer Cremer - GSK, United Kingdom

Safety, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist, in hyperlipidemic subjects and relative bioavailability/food effect of a solid formulation in healthy volunteers

Larry Blatt - Aligos Therapeutics, USA

Session 12: 2023 & Beyond: Gaps in knowledge and roadmap to action

back to top - digital content